This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
=== Prominent people with this condition === Danny DeVito, American actor, producer, and director Robert Reich, former United States Secretary of Labor under President Bill Clinton from 1993 to 1997 David Wetherill, British Paralympian table tennis athlete
=== Numbers and habitats of major phyla === The following table lists estimated numbers of described extant species for the major animal phyla, along with their principal habitats (terrestrial, fresh water, and marine), and free-living or parasitic ways of life. Species estimates shown here are based on numbers described scientifically; much larger estimates have been calculated based on various means of prediction, and these can vary wildly. For instance, around 25,000–27,000 species of nematodes have been described, while published estimates of the total number of nematode species include 10,000–20,000; 500,000; 10 million; and 100 million. Using patterns within the taxonomic hierarchy, the total number of animal species—including those not yet described—was calculated to be about 7.77 million in 2011.
=== Anxiety disorders === Escitalopram appears to be effective in treating generalized anxiety disorder, with relapse on escitalopram at 20% rather than placebo at 50%, which translates to a number needed to treat of 3.33. Escitalopram appears effective in treating social anxiety disorder as well.
Met-enkephalin, also known as metenkefalin (INN), sometimes referred to as opioid growth factor (OGF), is a naturally occurring, endogenous opioid peptide that has opioid effects of a relatively short duration. It is one of the two forms of enkephalin, the other being leu-enkephalin. The enkephalins are considered to be the primary endogenous ligands of the δ-opioid receptor, due to their high potency and selectivity for the site over the other endogenous opioids.
== Membership of professional bodies == Member of the Governing Council of the Pharmacists Council of Nigeria, Nnamdi Azikiwe University Member of the Nanomedicine Society of Nigeria Member of the Global Young Academy Member of the American Society for Cell biology Member of many other professional bodies including, Institute of Public Analysts of Nigeria; West African Society for Pharmacology, Nigeria; Society for Medicinal Plant Research, Germany; Pan African Medical Mycology Society, South Africa; International Society for Anti-infective Pharmacology; Materials Society of Nigeria; and, Nigerian Society of Forensic Scientists (Pioneer member of Board of Directors)
Sources: en.wikipedia.org
One method of feeding libraries into the microfluidic device uses single cell encapsulation, in which droplets contain a maximum of one cell each. This avoids confounding results that could be generated by having multiple cells, and consequently multiple genotypes, in a single droplet, while maximizing the efficiency of resource consumption. This method enables the detection of secreted proteins and proteins on the cell membrane. The addition of a cell lysate to the droplets, which breaks down the cellular membrane such that the intracellular species are freely available within the droplet, expands the capabilities of the single cell encapsulation method to analyze intracellular proteins. The library can also be made entirely in vitro (i.e., not in its biological/cellular context) such that the content of the droplet is exclusively a mutated DNA strand. The in vitro system requires PCR and the use of in vitro transcription and translation (IVTT) systems to generate the desired protein in the droplet for analysis. Sorting of droplets for directed evolution is primarily done by fluorescence detection (e.g., fluorescence-activated droplet sorting (FADS)), however recent developments in a absorbance-based sorting methods, known as absorbance-activated droplet sorting (AADS), have expanded the diversity of substrates that can undergo directed evolution through a droplet-based microfluidic device. Recently, sorting capability has even expanded to the detection of NADPH levels and has been used to create higher activity NADP-dependent oxidoreductases.
Due to their numerous sources indoors, concentrations of VOCs indoors are consistently higher (up to ten times higher) than outdoors. VOCs are emitted by thousands of indoor products. Examples include: paints, varnishes, waxes and lacquers, paint strippers, cleaning and personal care products, pesticides, building materials and furnishings, office equipment such as copiers and printers, correction fluids and carbonless copy paper, graphics and craft materials including glues and adhesives, permanent markers, and photographic solutions. Human activities such as cooking and cleaning can also emit VOCs. Cooking can release long-chain aldehydes and alkanes when oil is heated and terpenes can be released when spices are prepared and/or cooked. Cleaning products contain a range of VOCs, including monoterpenes, sesquiterpenes, alcohols and esters. Once released into the air, VOCs can undergo reactions with ozone and hydroxyl radicals to produce other VOCs, such as formaldehyde. Some VOCs are emitted directly indoors, and some are formed through the subsequent chemical reactions. The total concentration of all VOCs (TVOC) indoors can be up to five times higher than that of outdoor levels. New buildings experience particularly high levels of VOC off-gassing indoors because of the abundant new materials (building materials, fittings, surface coverings and treatments such as glues, paints and sealants) exposed to the indoor air, emitting multiple VOC gases.
=== Amino acids === Of the Free Amino Nitrogen (FAN) that make up YAN, the amino acids arginine, proline and glutamine are the most abundant followed by alanine, threonine, serine and aspartic acid in much smaller concentrations though trace amounts of most known amino acids can be found in grape must. Proline is usually the most concentrated and can represent up to 30% of the total amount of amino acids. The exact amount FAN will vary and can range 22 to 1242 mg of nitrogen/liter of YAN being derived from free amino acids.
During Operation Moduler, Cuban combat troops had remained well north of the Lomba River and declined to participate in the fighting, per Castro's instructions. In Luanda, President dos Santos summoned General Gusev and the senior Cuban general officer, Gustavo Fleitas Ramirez, for an urgent conference to discuss the worsening military situation and the failure of Operation Saluting October. Ramirez reminded dos Santos that Cuba had been opposed to the offensive from the beginning. Gusev lamented in his memoirs that "I informed [chief of the Soviet general staff] Akhromeyev about the result of the operation, but the most difficult task, in moral terms, was to inform the president of Angola, whom I had assured that the operation would succeed and that Savimbi would be crushed". On 25 November 1987, United Nations Security Council Resolution 602 was passed, condemning Operation Moduler as an illegal violation of Angolan sovereignty. The resolution expressed dismay at the continued presence of SADF troops in Angola and called for their unconditional withdrawal. South African foreign minister Pik Botha flatly dismissed the resolution out of hand, citing the unaddressed issue of Cuban linkage. He promised that the SADF would depart Angola once FAPLA's Cuban and Soviet advisers had likewise been withdrawn, or when their presence no longer threatened South African interests.
Sources: en.wikipedia.org
== History == Pseudoephedrine, along with ephedrine, occurs naturally in ephedra. This herb has been used for thousands of years in traditional Chinese medicine. Pseudoephedrine was first isolated and characterized in 1889 by the German chemists Ladenburg and Oelschlägel, who used a sample that had been isolated from Ephedra vulgaris by the Merck pharmaceutical corporation of Darmstadt, Germany. It was first synthesized in the 1920s in Japan. Subsequently, pseudoephedrine was introduced for medical use as a decongestant.
Electron paramagnetic resonance spectroscopy is similar to nuclear magnetic resonance (NMR), except it measures the spin excitement of unpaired electrons. Force spectroscopy is a set of techniques for the study of the interactions and the binding forces between individual molecules, although the name is somewhat misleading because there is no true matter-radiation interaction. Fourier-transform spectroscopy is an efficient method for processing spectra data obtained using interferometers. Fourier-transform infrared spectroscopy is an implementation of infrared spectroscopy. NMR also employs Fourier transforms. Gamma spectroscopy measures the gamma ray emissions from high energy processes including radioactive and astrophysical sources. Hadron spectroscopy studies the energy/mass spectrum of hadrons according to spin, parity, and other particle properties. Baryon spectroscopy and meson spectroscopy are types of hadron spectroscopy. Multispectral imaging and hyperspectral imaging is a method to create a complete picture of the environment or various objects, each pixel containing a full visible, visible near infrared, near infrared, or infrared spectrum. Inelastic electron tunneling spectroscopy uses the changes in current due to inelastic electron-vibration interaction at specific energies that can also measure optically forbidden transitions. Inelastic neutron scattering is similar to Raman spectroscopy, but uses neutrons instead of photons.
Only 249Bk is available in large quantities; it has a relatively short half-life of 330 days and emits mostly soft β-particles, which are inconvenient for detection. Its alpha radiation is rather weak (1.45×10−3% with respect to β-radiation), but is sometimes used to detect this isotope. 247Bk is an alpha-emitter with a long half-life of 1,380 years, but it is hard to obtain in appreciable quantities; it is not formed upon neutron irradiation of plutonium because β-decay of curium isotopes with mass number below 248 is not known. (247Cm would actually release energy by β-decaying to 247Bk, but this has never been seen.) The 20 isotopes of californium with mass numbers 237–256 are formed in nuclear reactors; californium-253 is a β-emitter and the rest are α-emitters. The isotopes with even mass numbers (250Cf, 252Cf and 254Cf) have a high rate of spontaneous fission, especially 254Cf of which 99.7% decays by spontaneous fission. Californium-249 has a relatively long half-life (352 years), weak spontaneous fission and strong γ-emission that facilitates its identification. 249Cf is not formed in large quantities in a nuclear reactor because of the slow β-decay of the parent isotope 249Bk and a large cross section of interaction with neutrons, but it can be accumulated in the isotopically pure form as the β-decay product of (pre-selected) 249Bk. Californium produced by reactor-irradiation of plutonium mostly consists of 250Cf and 252Cf, the latter being predominant for large neutron fluences, and its study is hindered by the strong neutron radiation.
Gueriguian, cited Rezulin's potential to harm the liver and the heart, and he questioned its viability in lowering blood sugar for patients with adult-onset diabetes, recommending against the drug's approval. After complaints from the drugmaker, Gueriguian was removed on November 4, 1996, and his review was purged by the FDA. Gueriguian and the company had a single meeting at which Gueriguian used "intemperate" language; the company said its objections were based on inappropriate remarks made by Gueriguian. Parke-Davis said at the advisory committee that the risk of liver toxicity was comparable to placebo and that additional data of other studies confirmed this. According to Peter Gøtzsche, when the company provided these additional data one week after approval, they showed a substantially greater risk for liver toxicity. The FDA approved the drug on January 29, 1997, and it appeared in pharmacies in late March. At the time, Dr. Solomon Sobel, a director at the FDA overseeing diabetes drugs, said in a New York Times interview that adverse effects of troglitazone appeared to be rare and relatively mild. Glaxo Wellcome received approval from the British Medicines Control Agency (MCA) to market troglitazone, as Romozin, in July 1997. After reports of sudden liver failure in patients receiving the drug, Parke-Davis and the FDA added warnings to the drug label requiring monthly monitoring of liver enzyme levels. Glaxo Wellcome removed troglitazone from the market in Britain on December 1, 1997.
{\displaystyle {\underset {\text{fluorapatite}}{{\ce {Ca5(PO4)3F}}}}+{\ce {5 H2SO4 + 10 H2O}}\longrightarrow {\underset {{\text{calcium sulfate}} \atop {\text{dihydrate}}}{{\ce {5 CaSO4*2H2O}}}}+{\ce {HF + 3 H3PO4}}}
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.